Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)

Philip J. Bergman; E. Gregory MacEwen; Ilene D. Kurzman; Carolyn J. Henry; Alan S. Hammer; Deborah W. Knapp; Ann Hale; Stephen A. Kruth; Mary K. Klein; Jeffrey Klausner; Alan M. Norris; Dudley McCaw; Rodney C. Straw; Stephen J. Withrow

doi:10.1111/j.1939-1676.1996.tb02031.x

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)

Philip J. Bergman, E. Gregory MacEwen, Ilene D. Kurzman, Carolyn J. Henry, Alan S. Hammer, Deborah W. Knapp, Ann Hale, Stephen A. Kruth, Mary K. Klein, Jeffrey Klausner, Alan M. Norris, Dudley McCaw, Rodney C. Straw, Stephen J. Withrow

Veterinary Clinical Sciences

Research output: Contribution to journal › Review article › peer-review

190 Scopus citations

Abstract

Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m². Neutropenia was the dose-limiting toxicity in this study.

Original language	English (US)
Pages (from-to)	76-81
Number of pages	6
Journal	Journal of veterinary internal medicine
Volume	10
Issue number	2
DOIs	https://doi.org/10.1111/j.1939-1676.1996.tb02031.x
State	Published - 1996

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1111/j.1939-1676.1996.tb02031.x

Find It

Find It at U of M Libraries

Cite this

Bergman, P. J., MacEwen, E. G., Kurzman, I. D., Henry, C. J., Hammer, A. S., Knapp, D. W., Hale, A., Kruth, S. A., Klein, M. K., Klausner, J., Norris, A. M., McCaw, D., Straw, R. C., & Withrow, S. J. (1996). Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). Journal of veterinary internal medicine, 10(2), 76-81. https://doi.org/10.1111/j.1939-1676.1996.tb02031.x

Bergman, PJ, MacEwen, EG, Kurzman, ID, Henry, CJ, Hammer, AS, Knapp, DW, Hale, A, Kruth, SA, Klein, MK, Klausner, J, Norris, AM, McCaw, D, Straw, RC & Withrow, SJ 1996, 'Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)', Journal of veterinary internal medicine, vol. 10, no. 2, pp. 76-81. https://doi.org/10.1111/j.1939-1676.1996.tb02031.x

@article{0935b934360e451cba1982d115c0c027,

title = "Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)",

abstract = "Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.",

author = "Bergman, {Philip J.} and MacEwen, {E. Gregory} and Kurzman, {Ilene D.} and Henry, {Carolyn J.} and Hammer, {Alan S.} and Knapp, {Deborah W.} and Ann Hale and Kruth, {Stephen A.} and Klein, {Mary K.} and Jeffrey Klausner and Norris, {Alan M.} and Dudley McCaw and Straw, {Rodney C.} and Withrow, {Stephen J.}",

year = "1996",

doi = "10.1111/j.1939-1676.1996.tb02031.x",

language = "English (US)",

volume = "10",

pages = "76--81",

journal = "Journal of veterinary internal medicine",

issn = "0891-6640",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Amputation and carboplatin for treatment of dogs with osteosarcoma

T2 - 48 cases (1991 to 1993)

AU - Bergman, Philip J.

AU - MacEwen, E. Gregory

AU - Kurzman, Ilene D.

AU - Henry, Carolyn J.

AU - Hammer, Alan S.

AU - Knapp, Deborah W.

AU - Hale, Ann

AU - Kruth, Stephen A.

AU - Klein, Mary K.

AU - Klausner, Jeffrey

AU - Norris, Alan M.

AU - McCaw, Dudley

AU - Straw, Rodney C.

AU - Withrow, Stephen J.

PY - 1996

Y1 - 1996

N2 - Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.

AB - Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.

UR - http://www.scopus.com/inward/record.url?scp=0030094970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030094970&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.1996.tb02031.x

DO - 10.1111/j.1939-1676.1996.tb02031.x

M3 - Review article

C2 - 8683484

AN - SCOPUS:0030094970

SN - 0891-6640

VL - 10

SP - 76

EP - 81

JO - Journal of veterinary internal medicine

JF - Journal of veterinary internal medicine

IS - 2

ER -

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this